- Ongoing, recruitingTherapeutic exploratory (Phase II)
A multi-center, randomized, placebo- and active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure
This study is looking into a new medication called XXB750 for people with heart failure. It hopes to see how well it works, what dose is best, and if it's safe compared to a dummy treatment or existing medicines.
For: Heart FailureNetherlands · Italy · Bulgaria - Ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema 2.4 mg/2.4 mg) once weekly versus semaglutide 2.4 mg, cagrilintide 2.4 mg and placebo in people with chronic kidney disease and type 2 diabetes living with overweight or obesity.
This study looks at a new combination medicine, CagriSema, for people with type 2 diabetes, kidney disease, and overweight or obesity. It compares CagriSema to existing treatments and a dummy medicine to see how it affects kidney health, weight, and blood sugar, while checking for side effects.
For: Chronic Kidney Disease · Type 2 diabetesSpain · Hungary · Poland - AuthorisedTherapeutic use (Phase IV)
NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; a prospective randomized trial
This study looks at how certain blood pressure and heart medications might help people with type 2 diabetes, who haven't had heart problems before, to avoid future heart issues. It focuses on a specific blood marker (NT-proBNP) to guide treatment.
For: Diabetes mellitus Type 2Spain · Austria